News Archive

If you want to change patient and provider behavior to improve a patient’s health, will an informational mailer make a difference?

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health with support from the Duke Clinical Research Institute shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – substantially improved clinical status and reduced deaths.

A recent paper from Duke Clinical Research Institute (DCRI) faculty on behalf of the American Gastroenterological Association (AGA) provides new tools for health care providers treating patients wi

The greatest story yet untold from the pandemic is about the incredible generosity of people who stepped up to help their communities by participating in research.

Overall rates at which stroke patients refuse treatment with tissue plasminogen activator (tPA) are low, yet eligible non-Hispanic Black patients are more likely to decline tPA than non-Hispanic Wh

A recent publication reports on an analysis of how study-specific fitness-for-use was addressed amongst pragmatic clinical trials that utilize real-world data (RWD), and makes recommendations to de

An industry emphasis on improving inclusion and diversity in clinical trials continues to grow, but strategies to achieve more balanced representation in research and clinical care remain elusive.

The DCRI celebrates its faculty members who recently received prestigious honors as part of Duke Medical School’s 2022 annual awards.

The SPIRRIT-HFpEF trial, being led by Sweden’s Karolinska Institutet and the U.S.’s Duke Clinical Research Institute, is a randomized pragmatic clinical trial of spironolactone or eplerenone vs usu

COVID-19 health care workers experienced high rates of potential moral injury that are comparable to rates among military veterans, according to a collaborative study between Duke University, Vanderbilt University, and the Department of Veterans Affairs (VA).